Search results for "Infectious diseases"
Research, regulators consider booster dose of COVID-19 vaccine
FDA advisors recommended boosters for older and high-risk patients. The latest COVID-19 research looked at vaccine effectiveness, remdesivir's effects, an early indicator of vaccine-induced immune thrombotic thrombocytopenia, and rates of follow-up after hospitalization.
https://immattersacp.org/weekly/archives/2021/09/21/1.htm
21 Sep 2021
ACP supports National Immunization Awareness Month, urges vaccination discussion with patients
ACP is committed to helping raise adult immunization rates, especially among patients with chronic conditions.
https://immattersacp.org/weekly/archives/2019/07/30/5.htm
30 Jul 2019
Studies look at COVID-19 vaccine boosters; ACP, Annals forum tackles challenging clinical questions
Two Israeli studies showed that vaccine boosters reduced rates of infection and severe disease. Experts gathered for the seventh ACP and Annals of Internal Medicine virtual forum on COVID-19. The FDA authorized a monoclonal antibody for pre-exposure prophylaxis in certain patients.
https://immattersacp.org/weekly/archives/2021/12/14/1.htm
14 Dec 2021
Pandemic enters new phase with end of PHE
COVID-19 isn't gone, but the end of the U.S. public health emergency does mark some significant changes.
https://immattersacp.org/archives/2023/06/pandemic-enters-new-phase-with-end-of-phe.htm
1 Jun 2023
CDC issues interim guidance on evaluation, treatment of suspected vaping injuries
The evaluation of patients with suspected e-cigarette, or vaping, product use-associated lung injury (EVALI) should include pulse oximetry, chest X-ray, and, in some cases, chest CT, the CDC advised.
https://immattersacp.org/weekly/archives/2019/10/22/2.htm
22 Oct 2019
New data on delta variant of COVID-19 and vaccines
Recent research found that the risk of myocarditis and both arterial and venous clots is higher with COVID-19 infection than with vaccine administration. Other studies show that the COVID-19 delta variant has been associated with reduced mRNA vaccine effectiveness (from 91% to 66%) and an overall increased severity of illness.
https://immattersacp.org/weekly/archives/2021/08/31/1.htm
31 Aug 2021
Latest research looks at prolonged symptoms, drug treatments in COVID-19
Two studies found symptoms to be common months to a year after COVID-19 infection, while other research found benefits from interleukin-6 inhibitors but no significant effects of ivermectin, remdesivir, and hydroxychloroquine.
https://immattersacp.org/weekly/archives/2021/07/13/1.htm
13 Jul 2021
CDC issues interim guidance on measles infection control and prevention in health care
New government guidance covers what is acceptable evidence of immunity to measles and how to respond if health care personnel are exposed to the disease.
https://immattersacp.org/weekly/archives/2019/07/30/4.htm
30 Jul 2019
Oral lefamulin noninferior to oral moxifloxacin in treating community-acquired bacterial pneumonia
Approved by the FDA in August, lefamulin is an “important addition to the current antibiotic armamentarium,” although barriers to use will likely include cost and tolerability concerns, an editor's note said.
https://immattersacp.org/weekly/archives/2019/10/01/2.htm
1 Oct 2019
DEI or DIE?
The College has become a leader in the world of justice, equity, diversity, and inclusion. While it is tempting to feel a sense of accomplishment, there is a gnawing feeling that more needs to be done.
https://immattersacp.org/archives/2021/05/dei-or-die.htm
1 May 2021